Breaking News Instant updates and real-time market news.

MDCO

The Medicines Co.

$51.92

1.03 (2.02%)

04:55
11/16/19
11/16
04:55
11/16/19
04:55

Roth Capital pharmaceuticals analysts to hold a luncheon

Analysts host Dr. John Kastelein, Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, who discusses Inclisiran's ORION Trials at a Luncheon Meeting being held in Philadelphia on November 16.

  • 16

    Nov

MDCO The Medicines Co.
$51.92

1.03 (2.02%)

10/02/19
RILY
10/02/19
NO CHANGE
Target $95
RILY
Buy
The Medicines Co. price target raised to $95 from $74 at B. Riley FBR
B. Riley FBR analyst Mayank Mamtani raised his price target for The Medicines Co. (MDCO) to $95 from $74 and added the shares to FBR's Alpha Generator List. The analyst has "heightened conviction" in inclisiran taking a dominant market share in the anti-PCSK9 marketplace, particularly at the expense of Regeneron's (REGN) Praluent. Mamtani's penetration-share scenario analysis suggests worldwide peak sales of $4.1B to $8.0B. The analyst keeps a Buy rating on The Medicines Co. The stock is yet to still reflect last week's "strong" Phase III Orion program execution and evidence generation on safety, efficacy, and durability of effect to reaffirm inclisiran's differentiated clinical profile, Mamtani tells nivestors in a research note.
10/10/19
JEFF
10/10/19
DOWNGRADE
Target $50
JEFF
Hold
The Medicines Co. downgraded to Hold from Buy at Jefferies
Jefferies analyst Biren Amin downgraded The Medicines Co. to Hold from Buy with a price target of $50, up from $44.
10/10/19
JEFF
10/10/19
DOWNGRADE
Target $50
JEFF
Hold
Jefferies downgrades The Medicines Co. on 'aggressive' inclisiran estimates
Jefferies analyst Biren Amin downgraded The Medicines Co. to Hold from Buy with a price target of $50, up from $44. After We conducting a doctor survey, the analyst thinks inclisiran consensus estimates are "too aggressive" and that The Medicines Co shares appear fully valued. While inclisiran leads in market share for PCSK9i, it is essentially split between inclisiran and Repath, Amin tell investors in a research note after polling 50 cardiologists. Based on the feedback, he lowered his 2026 inclisiran sales estimate to $1.4B from $1.7B, below the current consensus at $2.6B.
10/31/19
JEFF
10/31/19
NO CHANGE
Target $50
JEFF
Medicines Co. 'going concern' language introduces added risk, says Jefferies
Jefferies analyst Biren Amin said new disclosures in The Medicines Company's 10-Q regarding 2022 convertible notes introduces an additional risk as the company's balance sheet is not strong and if holders convert by December the company could require additional near-term funding. The 10-Q stated that if the notes are called and the company can't raise sufficient funds that "there is substantial doubt about the company's ability to continue as a going concern," Amin pointed out. He keeps a Hold rating on Medicines Co. shares.

TODAY'S FREE FLY STORIES

AZO

AutoZone

$1,250.39

79.085 (6.75%)

07:33
12/11/19
12/11
07:33
12/11/19
07:33
Recommendations
AutoZone analyst commentary  »

AutoZone price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 18

    Dec

DBI

Designer Brands

$14.18

-2.83 (-16.64%)

07:32
12/11/19
12/11
07:32
12/11/19
07:32
Recommendations
Designer Brands analyst commentary  »

Designer Brands price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLCM

Bellicum Pharmaceuticals

$0.80

-0.009 (-1.12%)

07:32
12/11/19
12/11
07:32
12/11/19
07:32
Hot Stocks
Bellicum Pharmaceuticals licenses CaspaCIDe Safety Switch to MD Anderson »

Bellicum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QRVO

Qorvo

07:31
12/11/19
12/11
07:31
12/11/19
07:31
Recommendations
Qorvo analyst commentary  »

Qorvo price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVGO

Broadcom

$315.10

0.61 (0.19%)

07:31
12/11/19
12/11
07:31
12/11/19
07:31
Recommendations
Broadcom analyst commentary  »

Broadcom price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

OMCL

Omnicell

$82.06

2.03 (2.54%)

07:31
12/11/19
12/11
07:31
12/11/19
07:31
Recommendations
Omnicell analyst commentary  »

Omnicell price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWW

Grainger

$323.51

-0.83 (-0.26%)

07:29
12/11/19
12/11
07:29
12/11/19
07:29
Upgrade
Grainger rating change  »

Grainger upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

PLCE

Children's Place

$70.67

0.68 (0.97%)

07:29
12/11/19
12/11
07:29
12/11/19
07:29
Hot Stocks
Children's Place down 17% to $58.20 after lowering FY19 guidance »

The company's Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

BBSI

Barrett Business

$89.45

1.85 (2.11%)

07:29
12/11/19
12/11
07:29
12/11/19
07:29
Initiation
Barrett Business initiated  »

Barrett Business…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

MA

MasterCard

$288.56

-0.48 (-0.17%)

07:28
12/11/19
12/11
07:28
12/11/19
07:28
Recommendations
MasterCard analyst commentary  »

MasterCard price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROK

Rockwell Automation

$199.78

0.89 (0.45%)

07:28
12/11/19
12/11
07:28
12/11/19
07:28
Upgrade
Rockwell Automation rating change  »

Rockwell Automation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBT

Welbilt

$16.32

-0.14 (-0.85%)

07:27
12/11/19
12/11
07:27
12/11/19
07:27
Downgrade
Welbilt rating change  »

Welbilt downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCI

Crown Castle

$134.00

-1.93 (-1.42%)

07:26
12/11/19
12/11
07:26
12/11/19
07:26
Conference/Events
Crown Castle management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

THDDY

TV Asahi

$0.00

(0.00%)

07:22
12/11/19
12/11
07:22
12/11/19
07:22
Initiation
TV Asahi initiated  »

TV Asahi initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEM

Agnico Eagle

$59.19

-0.11 (-0.19%)

07:21
12/11/19
12/11
07:21
12/11/19
07:21
Upgrade
Agnico Eagle rating change  »

Agnico Eagle upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOLD

Barrick Gold

07:21
12/11/19
12/11
07:21
12/11/19
07:21
Upgrade
Barrick Gold rating change  »

Barrick Gold upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FQVLF

First Quantum Minerals

$0.00

(0.00%)

07:21
12/11/19
12/11
07:21
12/11/19
07:21
Downgrade
First Quantum Minerals rating change  »

First Quantum Minerals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FJTNY

Fuji Media

$0.00

(0.00%)

07:21
12/11/19
12/11
07:21
12/11/19
07:21
Initiation
Fuji Media initiated  »

Fuji Media initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVFM

Evofem

$6.30

0.03 (0.48%)

07:19
12/11/19
12/11
07:19
12/11/19
07:19
Recommendations
Evofem analyst commentary  »

Evofem price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PB

Prosperity Bancshares

$70.40

-0.31 (-0.44%)

07:18
12/11/19
12/11
07:18
12/11/19
07:18
Downgrade
Prosperity Bancshares rating change  »

Prosperity Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CASY

Casey's General Stores

$158.77

-16.56 (-9.45%)

07:17
12/11/19
12/11
07:17
12/11/19
07:17
Recommendations
Casey's General Stores analyst commentary  »

Casey's General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAG

IAMGold

$3.40

-0.05 (-1.45%)

07:16
12/11/19
12/11
07:16
12/11/19
07:16
Hot Stocks
IAMGold increases interest in Nelligan project by 24% for C$2.35M »

Vanstar Mining Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZO

AutoZone

$1,250.39

79.085 (6.75%)

07:16
12/11/19
12/11
07:16
12/11/19
07:16
Conference/Events
AutoZone management to meet with Morgan Stanley »

Group Dinner Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 18

    Dec

PRQR

ProQR Therapeutics

$9.09

0.44 (5.09%)

07:13
12/11/19
12/11
07:13
12/11/19
07:13
Hot Stocks
ProQR Therapeutics doses first patient in Phase 1/2 Aurora trial of QR-1123 »

ProQR Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTAI

BioXcel Therapeutics

$6.08

-0.07 (-1.14%)

07:12
12/11/19
12/11
07:12
12/11/19
07:12
Hot Stocks
BioXcel Therapeutics to expand BXCL701 study into multiple advanced solid tumors »

BioXcel Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.